A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

Inclusion Criteria:

• Diagnosis of DS must fulfill all of the following criteria:

1. Participants with seizure onset age >1 and <20 months

2. The participant has a history of at least 1 of the following seizure type(s):prolonged generalized tonic-clonic, hemiclonic, myoclonic, tonic, atonic,atypical absence, focal impaired awareness, nonconvulsive status epilepticus

• The participant has a current occurrence of at least 1 of the following countablemotor seizure types: generalized tonic-clonic, tonic (bilateral), clonic (bilateral), atonic (bilateral) with truncal/leg involvement, focal motor (includinghemiclonic), and focal to bilateral tonic-clonic

• The participant has demonstrated an average of at least 4 countable motor seizuresper month for the 3 months prior to Screening.

• The participant has been taking 1 to 4 antiseizure medications (ASMs) at a stabledose for at least 4 weeks prior to Screening.

• The participant, parent, or caregiver is willing and able (in the judgment of theinvestigator) to comply with completion of the diaries throughout the study.

• The participant must be willing and able to provide written informed consent.

Exclusion Criteria:

• The participant has a history of infantile/epileptic spasms.

• The participant has been admitted to a medical facility for treatment of statusepilepticus requiring mechanical ventilation within 3 months prior to Screening.

• The participant has a neurodegenerative disorder as indicated by magnetic resonanceimaging or genetic testing.

• The participant has an acquired lesion/injury unrelated to the primary etiology thatcould contribute as a secondary cause of seizures.

• The participant is receiving exclusionary medications.

• The participant is currently using any cannabis product or cannabidiol that is notin oral solution/capsule/tablet form, not obtained from a government-approveddispensary, or contains ≥50% Delta-9-tetrahydrocannabinol (THC).

• The participant has unstable, clinically significant neurologic (other than thedisease being studied, eg, recurrent strokes), psychiatric, cardiovascular (eg,pulmonary arterial hypertension, cardiac valvulopathy, orthostatichypotension/tachycardia), pulmonary, hepatic, renal, metabolic, gastrointestinal,urologic, immunologic, hematopoietic, or endocrine disease or other abnormalitywhich may impact the ability of the participant to participate or potentiallyconfound the study results.

• The participant is unwilling to comply with any of the study requirements ortimelines.